{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:05:46Z","timestamp":1777878346060,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Waldenstr\u00f6m\u2019s macroglobulinemia (WM) is a B-cell neoplasia characterized by the infiltration of lymphoplasmacytic lymphoma cells in the bone marrow and abnormal secretion of IgM paraprotein. Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), showed high efficacy in WM clinical trials. However, there is limited real-world data regarding its effectiveness and safety in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The MACRO study aimed to investigate the clinical, genetic, and demographic characteristics of WM patients treated with ibrutinib-based therapies in Spain. Key secondary objectives included describing effectiveness and safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective observational.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This multicenter, observational, retrospective study included adult patients diagnosed with symptomatic WM treated with ibrutinib since its commercial approval in Spain in 2016. Data were collected from 19 hospitals through retrospective medical chart reviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty-two eligible patients were recruited. The median age at the start of ibrutinib treatment was 74\u2009years. Most of patients were male (65.4%) and had an Eastern Cooperative Oncology Group performance status of 0\u20131 (89.7%). Overall response rate was 92.2%, with a major response rate of 80.5%. Median progression-free survival (PFS) was 57.2\u2009months, and the estimated 2-year overall survival rate was 89.2%. No significant differences in PFS were identified based on the parameters defining risk subgroups, nor did they vary according to treatment line, initial dose, or treatment schedule. Most common adverse events included bleeding (30.8%), diarrhea (23.1%), and infections (15.4%), with most of them being grades 1\u20132. No new safety signs were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study presents real-world evidence on the characteristics and outcomes of WM patients treated with ibrutinib in Spain, showing it to be effective with a manageable safety profile consistent with clinical trial results. These findings support ibrutinib as a valuable treatment option for WM in real-world settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251379670","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T11:51:27Z","timestamp":1759751487000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Observational retrospective study of the treatment of Waldenstr\u00f6m\u2019s macroglobulinemia with ibrutinib in routine clinical practice in Spain"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"first","affiliation":[{"name":"Amyloidosis and Multiple Myeloma Unit, Department of Hematology, Hospital Cl\u00ednic of Barcelona, Universitat de Barcelona, Villarroel 170, Barcelona, 08036, Spain"},{"name":"Hospital Cl\u00ednic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[{"name":"Hospital Universitario de La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valent\u00edn","family":"Caba\u00f1as","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de la Arrixaca, Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Freiria","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Castell\u00f3n, Castell\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Askari","sequence":"additional","affiliation":[{"name":"Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Lorenzo P\u00e9rez","sequence":"additional","affiliation":[{"name":"Hospital \u00c1lvaro Cunqueiro, Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Abril","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias I Pujol, ICO Badalona, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"L\u00f3pez Pardo","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Pinz\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital del Mar, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"D\u00edaz G\u00e1lvez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neus","family":"Amer","sequence":"additional","affiliation":[{"name":"Hospital Son Ll\u00e0tzer (IdISBa), Palma de Mallorca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Ram\u00edrez P\u00e1yer","sequence":"additional","affiliation":[{"name":"Hospital Universitario Central de Asturias, Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricarda","family":"Garc\u00eda S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Magdalena","family":"Alcal\u00e1","sequence":"additional","affiliation":[{"name":"Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Capote","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta del Mar, C\u00e1diz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Bolumburu","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, S.A., Johnson &amp; Johnson, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Rubio-Azpeitia","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, S.A., Johnson &amp; Johnson, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda Sanz","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18036"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50082"},{"key":"e_1_3_4_4_2","article-title":"Waldenstrom\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Kastritis E","year":"2018","unstructured":"Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenstrom\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv270.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_5_2","unstructured":"Fundaci\u00f3n Josep Carreras contra la leucemia. La macroglobulinemia de Waldestr\u00f6m https:\/\/www.fcarreras.org\/es\/macroglobulinemia-de-waldenstrom_370111 (accessed July 18 2024)."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-475111"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.02.005"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30224-6"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01417-9"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00555"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1497"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00838"},{"key":"e_1_3_4_14_2","article-title":"Treatment and survival outcomes of Waldenstrom macroglobulinemia in Latin American patients: a multinational retrospective cohort study","volume":"8","author":"Riva E","year":"2022","unstructured":"Riva E, Duarte PJ, Valcarcel B, et al. Treatment and survival outcomes of Waldenstrom macroglobulinemia in Latin American patients: a multinational retrospective cohort study. JCO Glob Oncol 2022; 8: e2100380.","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05113-9"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18643"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16168"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000363"},{"key":"e_1_3_4_19_2","unstructured":"Agency EM. Imbruvica (ibrutinib) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imbruvica (2014 accessed December 2024)."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169776"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17225"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S267938"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03144.x"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006106"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16088"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02830"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251379670","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251379670","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251379670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:55Z","timestamp":1777591075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251379670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"alternative-id":["10.1177\/20406207251379670"],"URL":"https:\/\/doi.org\/10.1177\/20406207251379670","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20406207251379670"}}